Patent application number | Description | Published |
20080274200 | DOSE TITRATABLE LIQUID DOSAGE FORMS OF ACID LABILE DRUGS - Provided herein are pharmaceutical formulations comprising micro-granules and a liquid suspension vehicle having a pH less than 6.0 and a viscosity sufficient to suspend the micro-granules. The micro-granules typically contain a PPI which therefore makes the above formulation, as well as kits for making the above formulation, useful for alleviating the symptoms of gastrointestinal disorders or diseases. | 11-06-2008 |
20080292710 | Liquid Dosage Forms Of Acid Labile Drugs - Liquid formulations of acid-labile drugs are provided. The formulations generally comprise micro-granules comprising an acid-labile drug coated with an enteric coating and a liquid vehicle having a pH less than 6.0. The components of the formulation can separately provided in the form of kits. The formulations and kits may be used to treat patients suffering from disorders for which the acid labile drugs are indicated. | 11-27-2008 |
20090042887 | Methods for Preventing or Reducing the Number of Gout Flares Using Xanthine Oxidoreductase Inhibitors and Anti-Inflammatory Agents - The present invention relates to methods of preventing gout flares in a subject in need thereof by administering to the subject a therapeutically effective amount of at least one xanthine oxidoreductase inhibiting compound or salt thereof and at least one non-steroidal anti-inflammatory drug for a period of six months on a regular basis. | 02-12-2009 |
20090215830 | Multiple ppi dosage form - Herein provided are dosage forms (variously referred to as “formulations”) comprising a PPI that is released from the dosage form as a first and a second dose. Each dose of PPI is present in an amount sufficient to raise the plasma levels of the PPI to at least 100 ng/ml. | 08-27-2009 |
20090220621 | Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination - A method for treating gastric acid disorders with a non-enteric coated proton pump inhibitor in a pharmaceutically acceptable carrier including a bicarbonate salt of a Group IA metal and a carbonate salt of a Group IA metal; and a pharmaceutical composition of a non-enteric coated proton pump inhibitor in a pharmaceutically acceptable carrier including a bicarbonate salt of a Group IA metal and a carbonate salt of a Group IA metal are disclosed. A presently preferred proton pump inhibitor is lansoprazole, a presently preferred bicarbonate salt is sodium bicarbonate, and a presently preferred carbonate salt is sodium carbonate. The composition is a fast-acting formulation which reduces the undesirable belching associated with proton pump inhibitor formulations that contain high doses of sodium bicarbonate. | 09-03-2009 |
20100004291 | LIQUID DOSAGE FORMS OF NON-ENTERICALLY COATED ACID-LABILE DRUGS - Provided herein are formulations of acid labile drugs, such as proton pump inhibitors (PPI). The formulations comprise a PPI and a liquid vehicle typically having a pH greater than 6.5 and a viscosity sufficient to maintain a uniform suspension of the PPI for 15 minutes. | 01-07-2010 |
20100086572 | RATIONAL PPI DOSAGE FORMS - The invention herein provides for a continuous release dosage form (which is referred to as “dosage forms”) comprising a continuous release dosage form, which releases PPI in a first release portion directly to the gastric mucosa and a second release portion to provide for sustained plasma levels resulting in increased therapeutic efficacy. | 04-08-2010 |
20110180448 | PACKAGING SYSTEM FOR SEPARATELY STORING AND DISPENSING TOGETHER SEPARATE MEDICATION COMPONENTS - The present invention relates to a packaging system intended to simplify the usage of multiple medications stored separately and used together, thereby minimize the non-compliant use of the multiple medications. Generally, the separate medications are grouped together on a per dose basis in a plurality of blister pack recesses. A single cover sheet is used to commonly seal the related medications to be used together, such that when the corresponding cover sheet is removed the multiple medications are commonly accessed. | 07-28-2011 |
20110311620 | NOVEL MODIFIED RELEASE DOSAGE FORMS OF XANTHINE OXIDOREDUCTASE INHIBITOR OR XANTHINE OXIDASE INHIBITORS - The present disclosure relates to novel dosage forms of xanthine oxidoreductase inhibitors. | 12-22-2011 |
20120142737 | PHARMACEUTICAL COMPOSITIONS OF A NON-ENTERIC COATED PROTON PUMP INHIBITOR WITH A CARBONATE SALT AND BICARBONATE SALT COMBINATION - A method for treating gastric acid disorders with a non-enteric coated proton pump inhibitor in a pharmaceutically acceptable carrier including a bicarbonate salt of a Group IA metal and a carbonate salt of a Group IA metal; and a pharmaceutical composition of a non-enteric coated proton pump inhibitor in a pharmaceutically acceptable carrier including a bicarbonate salt of a Group IA metal and a carbonate salt of a Group IA metal are disclosed. A presently preferred proton pump inhibitor is lansoprazole, a presently preferred bicarbonate salt is sodium bicarbonate, and a presently preferred carbonate salt is sodium carbonate. The composition is a fast-acting formulation which reduces the undesirable belching associated with proton pump inhibitor formulations that contain high doses of sodium bicarbonate. | 06-07-2012 |
20120184584 | METHODS AND DRUG PRODUCTS FOR TREATING ALZHEIMER'S DISEASE - Provided herein are drug products with low dose pioglitazone for use in the treatment (e.g., delay of onset) of cognitive impairment of the Alzheimer's type. Methods of manufacture thereof are also provided. Further provided are methods of treatment for Alzheimer's disease including administering a drug product with low dose pioglitazone. The methods may include determining whether the subject is at risk of developing Alzheimer's disease based upon the subject's age and TOMM40 523 genotype. | 07-19-2012 |
20120252848 | LIQUID DOSAGE FORMS OF NON-ENTERICALLY COATED ACID-LABILE DRUGS - Provided herein are formulations of acid labile drugs, such as proton pump inhibitors (PPI). The formulations comprise a PPI and a liquid vehicle typically having a pH greater than 6.5 and a viscosity sufficient to maintain a uniform suspension of the PPI for 15 minutes. | 10-04-2012 |
20130245071 | MULTIPLE PPI DOSAGE FORM - Herein provided are dosage forms (variously referred to as “formulations”) comprising a PPI that is released from the dosage form as a first and a second dose. Each dose of PPI is present in an amount sufficient to raise the plasma levels of the PPI to at least 100 ng/ml. | 09-19-2013 |